Subconstrictor Doses of Neuropeptide Y Potentiate α 1 -Adrenergic Venoconstriction In Vivo
- 1 September 1996
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 28 (3) , 483-487
- https://doi.org/10.1161/01.hyp.28.3.483
Abstract
The 36–amino acid human neuropeptide Y is a vasoactive compound released after stimulation of the sympathetic nervous system. In addition to its direct and long-lasting vasopressor effects, it may potentiate the constrictor action of catecholamines and other vasoconstrictors at doses that do not per se exert vascular effects. Using the hand vein compliance technique, we have previously shown that neuropeptide Y also constricts superficial hand veins and that its effects may last for several hours. In this study, we investigated the local effect of neuropeptide Y on α 1 -adrenergic venoconstriction in nine healthy volunteers at dose rates that did not affect venous compliance. On separate days, cumulative dose-response curves to phenylephrine alone and with coadministration of 1 or 30 pmol neuropeptide Y per minute were constructed, and the responses were fitted to a four-parameter logistic equation. Neuropeptide Y dose dependently shifted the phenylephrine curves toward lower dose rates without affecting maximal effects. ED 50 values for phenylephrine alone and with 1 or 30 pmol/min neuropeptide Y were 4.0, 4.9 ( P =NS versus control), and 1.2 ( P <.005) nmol/min, respectively. Comparison with neuropeptide Y dose-response curves revealed that the interaction was synergistic. These are the first data in humans to show that small dose rates of neuropeptide Y may potentiate α-adrenergic effects in vivo. Because this interaction occurs at estimated local concentrations nearly achieved in humans, these studies suggest that neuropeptide Y might modulate the filling of this capacitance system in vivo.Keywords
This publication has 28 references indexed in Scilit:
- Evidence for Activation of the Sympathetic Nervous System by Recombinant Human Interleukin-1?? in HumansJournal of Immunotherapy, 1993
- Age‐related changes of exercise‐induced plasma catecholamines and neuropeptide Y responses in normal human subjectsActa Physiologica Scandinavica, 1992
- Elevation of plasma neuropeptide Y‐like immunoreactivity and noradrenaline during myocardial ischaemia in manJournal of Internal Medicine, 1990
- Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failureCardiovascular Research, 1990
- Cigarette smoke‐induced elevation of plasma neuropeptide Y levels in manClinical Physiology and Functional Imaging, 1989
- Neuropeptide Y Potentiates Contraction and Inhibits Relaxation of Rabbit Coronary ArteriesJournal of Cardiovascular Pharmacology, 1987
- Effects of Antihypertensive Drugs on Sympathetic Vascular Control in Relation to Neuropeptide YJournal of Cardiovascular Pharmacology, 1987
- Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in manLife Sciences, 1986
- Increases in plasma neuropeptide Y concentrations during sympathetic activation in manJournal of the Autonomic Nervous System, 1986
- Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptideNature, 1982